[1] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol, 2020, 73:202-209.
[2] Angulo P, Kleiner DE, Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 2015, 149:389-397.
[3] Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol, 2020, 73:1322-1332.
[4] Segovia-Miranda F, Morales-Navarrete H, Kucken M, et al. Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression. Nat Med, 2019, 25:1885-1893.
[5] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non- alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2019, 394:2184-2196.
[6] Harrison SA, Neff G, Guy CD, et al. Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double- blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis. Gastroenterology, 2021, 160:219-231.e1.
[7] Iruarrizaga-Lejarreta M, Varela-Rey M, Fernandez-Ramos D, et al. Role of Aramchol in steatohepatitis and fibrosis in mice. Hepatol Commun, 2017, 1:911-927.
[8] Newsome PN, Sasso M, Deeks JJ, et al. FibroScan- AST (FAST) score for the non- invasive identification of patients with non- alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol. Hepatol, 2020, 5:362-373.
[9] Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus. J Hepatol, 2020, 73:9-11.
[10] Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc, 1980, 55:434-438.
[11] Abdelmalek MF. Nonalcoholic fatty liver disease: another leap forward. Nat Rev Gastroenterol Hepatol, 2021, 18:85-86. |
